Detalhe da pesquisa
1.
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
Front Immunol;
14: 1259725, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37928549
2.
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
PLoS One;
17(8): e0273340, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36001576